Development of novel oncofetal antigen targeting immunotherapy for refractory ovarian carcinoma

• Project/Area Number: 21592127
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Nagoya University
• Principal Investigator: SHIBATA Kiyosumi 名古屋大学, 大学院・医学系研究科, 准教授 (90335026)
• Co-Investigator(Kenkyū-buntansha): KIKKAWA Fumitaka 名古屋大学, 大学院・医学系研究科, 教授 (40224985)
• Project Period (FY): 2009 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000); Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 難治性卵巣がん / 免疫療法 / Glypican-3 / ペプチドワクチン / 臨床試験 / 卵巣明細胞腺癌 / GPC-3 / glypican-3 / CTL / 卵巣がん / がん胎児性抗原

Research Abstract

We started a phase II clinical trial of HLA-A24 and A2 restrictive Glypican-3(GPC3) peptide vaccine for clear cell carcinoma of ovary as one of the immunotherapy for refractory ovarian carcinoma. We confirmed the safety of the vaccine and GPC3 specific CTL by Ex vivo IFN

Research Products

• [Journal Article] Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma (2011)
  • Author(s): Suzuki S, Yoshikawa T, Hirosawa T, Shibata K, Kikkawa F, Akatsuka Y, Nakatsura T
  • Journal Title: Cancer Sci Volume: 102(9) Pages: 1622-9
  • NAID: 10030242806
  • Peer Reviewed
• [Journal Article] Mismatched human leukocyte antigen class II-restricted CD8. cytotoxic T cells may mediate selective graft-versus-leukemia effects following allogeneic hematopoietic cell transplantation (2011)
  • Author(s): Hirosawa T, Torikai H, Yanagisawa M, Kamei M, Imahashi N, Demachi-Okamura A, Tanimoto M, Shiraishi K, Ito M, Miyamura K, Shibata K, Kikkawa F, Morishima Y, Takahashi T, Emi N, Kuzushima K, Akatsuka Y
  • Journal Title: Cancer Sci Volume: 102(7) Pages: 1281-1286
  • NAID: 10029295003
  • Peer Reviewed
• [Journal Article] Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma (2011)
  • Author(s): Suzuki S, Yoshikawa T, Hirosawa T, Shibata K, Kikkawa F, Akatsuka Y, Nakatsura T.
  • Journal Title: Cancer Sci Volume: 102 Issue: 9 Pages: 1622-9
  • DOI: 10.1111/j.1349-7006.2011.02003.x
  • NAID: 10030242806
  • Peer Reviewed
• [Journal Article] Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells. (2010)
  • Author(s): Sakurai M
  • Journal Title: Gynecol Oncol. Volume: 119(2) Pages: 332-336
  • Peer Reviewed
• [Journal Article] Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary. (2010)
  • Author(s): Umezu T
  • Journal Title: J Clin Pathol. Volume: 63(11) Pages: 962-966
  • Peer Reviewed
• [Presentation] 婦人科癌に対する特異的癌免疫療法-明細胞腺癌を対象としたGPC3特異的ペプチドワクチン療法の第I, II相臨床試験 (2011)
  • Author(s): 柴田清住、吉川史隆
  • Organizer: 第70回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場
  • Year and Date: 2011-10-05
• [Presentation] 卵巣明細胞腺がんに対するGPC3由来ペプチドワクチン療法の可能性 (2011)
  • Author(s): 鈴木史朗、吉川聡明、廣澤友也、柴田清住、吉川史隆、中面哲也
  • Organizer: 第70回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場
  • Year and Date: 2011-10-05
• [Presentation] 婦人科癌に対する特異的癌免疫療法-明細胞腺癌を対象としたGPC3特異的ペプチドワクチン療法の第I,II相臨床試験 (2011)
  • Author(s): 柴田清住、吉川史隆
  • Organizer: 第70回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場
  • Year and Date: 2011-10-05
• [Presentation] 内因性HLAの発現を抑制し目的のHLA-A24を発現する人工抗原を用いた卵巣がんを傷害するCTLの誘導 (2011)
  • Author(s): 近藤紳司、岡村文子、牧寛之、Rong Zhang、植村靖史、藤田貢、山本英子、柴田清住、吉川史隆、葛島清隆
  • Organizer: 第70回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場
  • Year and Date: 2011-10-04